Docquity, the smart healthcare platform empowering global pharmaceutical companies to interact with the largest network of healthcare practitioners (HCPs) in Southeast Asia, has announced the successful completion of its $44m Series C funding round, led by ITOCHU Corporation and including iGlobe Partners, Alkemi, Global Brain, KDV and Infocom.

Docquity’s platform is home to a network of over 350k verified HCPs across Southeast Asia. The platform offers networking opportunities as well as free-to-access, accredited continuing medical education via its partnerships with 250 medical associations. The company has serviced over 120 pharmaceutical customers, including 8 of the global top 10, who reach HCPs with education and marketing content on the platform and with virtual medical representative services.

ITOCHU Corporation is a leading Japanese general trading company, with a rich track record of investing in growth companies across multiple sectors. The company is well positioned to aid Docquity in its global ambitions, including entering the Japanese market.

IBIS Capital advised Docquity on its Series C fundraising process, attracting multiple offers from regional and international investors and leading to a 5x over-subscription to the Series C. The transaction achieved attractive terms for the founders and shareholders and enables Docquity to take advantage of significant global growth opportunities. The transaction is a demonstration of IBIS Capital’s health technology expertise and long-standing global network of relationships. The deal team was led by Jamie Ritchie and Bracy Fertig.

IBIS Capital is a specialist investment and corporate finance advisory group focussed on globally impactful tech sectors: education, health and food. Should you wish to learn about opportunities (acquisitions, investment partners or acquirers) in the digital health sector across the globe or to access our sector research, please contact us: Jamie Ritchie ( and Bracy Fertig (